STAT6 and Alzheimer disease: IL-4 and IL-13 significantly reduce the expression of key structural proteins of the skin barrier (such as filaggrin) by activating STAT6 (Figure 3), leading to an increase in transepidermal water loss that is typically measured, disrupting the integrity of the stratum corneum and exacerbating the severity of AD (8).